文献速递肾癌与肾肿瘤

cT1aN0M0肾细胞癌非手术治疗与主动治疗的生存比较:一项基于人群的研究

Non-surgical management vs active treatment in T1a renal cell carcinoma: a population-based study.
PubMed 文献 · BJU Int · 2025-11-13

这项基于瑞典肾细胞癌数据库的全国性队列研究纳入3989例cT1aN0M0肾细胞癌患者,比较非手术治疗(监测与观察等待)与主动治疗(手术与消融)的生存差异。中位随访4.1年,非手术治疗组全因死亡率和癌症特异性死亡率均显著高于主动治疗组。结论提示非手术治疗应与手术/消融相比生存更差,主要适用于预期寿命有限且肿瘤惰性的患者。

要点

  • 非手术治疗组全因死亡率38.9%,主动治疗组10.9%(P < 0.001)。
  • 非手术治疗组癌症特异性死亡率13.0%,主动治疗组3.4%(P < 0.001)。
  • 非手术治疗应主要考虑用于预期寿命有限且肿瘤惰性的患者。

核心结论

  • cT1aN0M0肾细胞癌非手术治疗与手术/消融相比与更差的生存相关。
  • 非手术治疗应主要提供给预期寿命有限且肿瘤惰性的患者。

研究设计与样本

  • 全国性真实世界基于人群的队列研究,数据来自瑞典肾细胞癌数据库(RCCBaSe)。
  • 纳入2011-2020年诊断为cT1aN0M0肾细胞癌并接受非手术治疗或主动治疗的3989例患者。
  • 采用标准Cox回归模型和竞争风险Cox回归模型分析生存差异。

主要发现

  • 3727例(93.4%)接受主动治疗,262例(6.6%)接受非手术治疗。
  • 非手术治疗组患者年龄显著更大且合并症负担更高。
  • 中位随访4.1年,非手术治疗组全因死亡率38.9%,主动治疗组10.9%(P < 0.001)。
  • 非手术治疗组癌症特异性死亡率13.0%,主动治疗组3.4%(P < 0.001)。
  • 较大肿瘤、较大年龄、男性、合并症增加、未婚或丧偶、可支配收入较低、透明细胞或乳头状RCC( compared with 嫌色细胞RCC)均与更差的总生存和癌症特异性生存独立相关。

临床怎么用

  • 对于cT1aN0M0肾细胞癌,手术或消融应作为多数患者的首选主动治疗方式。
  • 非手术治疗可考虑用于预期寿命有限且肿瘤惰性的患者。

局限性

  • 治疗分配并非随机化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare overall and cancer-specific survival for clinical (c)T1aN0M0 renal cell carcinoma (RCC) in patients treated with non-surgical management (NSM: surveillance and watchful waiting) or active treatment (surgery and ablative treatments). PATIENTS AND METHODS: In this nationwide real-world population-based cohort study, data on clinical, demographic, and socioeconomic factors as well as tumour characteristics and cause of death were retrieved from the Renal Cell Carcinoma Database Sweden (RCCBaSe) for 3989 patients diagnosed with cT1aN0M0 RCC, 2011-2020 and treated with either NSM or active treatment. Differences in survival between NSM and active treated patients were analysed using standard and competing-risks Cox regression models. RESULTS: In total, 3727 (93.4%) patients underwent active treatments, while 262 patients (6.6%) were treated with NSM. Patients in the NSM group were significantly older and had a higher comorbidity burden. During a median follow-up time of 4.1 years, all-cause mortality was significantly higher among the NSM (38.9%) than the actively treated (10.9%) patients (P < 0.001), as was cancer-specific mortality (13.0% vs 3.4%, P < 0.001). Larger tumours, older age, male sex, increased comorbidity, being unmarried or widowed, having lower disposable income, and having clear cell or papillary RCC compared with chromophobe RCC were all independently associated with poorer overall and cancer-specific survival. One of the limitations is that treatment allocation was not randomised. CONCLUSION: Non-surgical management of cT1aN0M0 RCC was associated with poorer survival compared with surgery/ablation and should be offered mainly for patients with limited life expectancy and indolent renal tumours.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Hashim BM, Rosenblad AK, Lundgren PO, et al. Non-surgical management vs active treatment in T1a renal cell carcinoma: a population-based study. BJU Int. 2025. PMID: 41230913. doi:10.1111/bju.70074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。